FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

Venky Venkatesh

Senior Director - Project Management C2N Diagnostics LLC

Tuesday 3rd February 2026

Novel Neurodegenerative Biomarkers for Precision Diagnostics and Clinical Trials

11:00 am

High Resolution Mass Spectrometry Assays
Non-invasive, affordable, scalable, and robustly clinically validated tests
PrecivityAD2™ Test: An Advanced Blood Test for Brain Amyloid Detection
eMTBR-tau243 – tangle specific novel biomarker for tau pathology Robust biomarkers for pharmacodynamic monitoring in clinical trails